Revenue Recognition - Schedule of net revenue from collaborative arrangements (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue Recognition and Collaboration Arrangements
Net revenue	$ 67,257	$ 97,862	$ 265,536	$ 284,186
Royalty revenue from a related party
Revenue Recognition and Collaboration Arrangements
Net revenue	62,150	97,862	260,429	284,186
GSK | Royalty revenue from a related party
Revenue Recognition and Collaboration Arrangements
Royalties	65,606	101,318	270,797	294,554
Less: amortization of capitalized fees paid to a related party	(3,456)	(3,456)	(10,368)	(10,368)
Net revenue	62,150	97,862	260,429	284,186
GSK | RELVAR/BREO
Revenue Recognition and Collaboration Arrangements
Royalties	55,663	54,092	170,753	176,398
GSK | ANORO
Revenue Recognition and Collaboration Arrangements
Royalties	9,943	11,641	28,015	34,101
GSK | TRELEGY
Revenue Recognition and Collaboration Arrangements
Royalties	$ 0	$ 35,585	$ 72,029	$ 84,055